C
Curve Therapeutics
Redefining drug discovery in order to make it more efficient and effective
About Curve Therapeutics
Curve Therapeutics, founded in 2019 as a spin-out from the University of Southampton, is a biotechnology firm focused on developing a new class of medicines for complex diseases, with an initial emphasis on oncology. The company's genesis lies in over a decade of research by its co-founder, Professor Ali Tavassoli, within the university's Department of Chemistry. Professor Tavassoli, now the Chief Scientific Officer, is a Professor of Chemical Biology whose research has centered on creating high-throughput screening platforms to discover inhibitors of protein-protein interactions. He is joined by co-founder and CEO, Dr. Simon Kerry, a life-science entrepreneur with over three decades of leadership experience in European biotech companies, including roles at Karus Therapeutics, Ablynx, and Advent Life Sciences.
The core of Curve Therapeutics' operations is its proprietary Microcycle® platform. This technology enables the direct functional screening of vast, genetically encoded libraries of cyclic peptides within live mammalian cells. This intracellular screening method is a key differentiator, as it allows for the identification of active molecules against challenging targets in their natural cellular environment, a feat difficult to achieve with conventional drug discovery techniques. The platform is designed to identify molecules that can modulate historically 'undruggable' targets, such as protein-protein and protein-DNA interactions, which are implicated in numerous cancers. The small, rigid structure of the identified Microcycles facilitates their subsequent development into small molecule drugs.
The company's business model is twofold, involving both in-house pipeline development and strategic collaborations with major pharmaceutical companies. A significant milestone is a global research collaboration with MSD (the trade name of Merck & Co., Inc.) potentially worth up to $1.7 billion, focused on discovering and validating modulators for up to five therapeutic targets in oncology and neurology. Curve Therapeutics has also built its own discovery pipeline, featuring assets like a first-in-class dual inhibitor of HIF-1 and HIF-2, which targets survival mechanisms in a majority of solid tumors, and an inhibitor of ATIC dimerization. To advance these programs, the company secured £40.5 million in a Series A financing round in February 2024, led by Pfizer Ventures and supported by investors such as British Patient Capital, Columbus Venture Partners, Advent Life Sciences, and Epidarex Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 36
- Open positions
- None listed
- Dealroom signal
- 72.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Microfluidics, Core AI, Spinout, AI Drug Discovery, Techbio, Techbio Drug Discovery, AI Applications, Digital Pharma, DT and LS
- Technology
- Artificial Intelligence
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Feb 2024 | $53M | $214M | Epidarex Capital · Columbus Venture Partners · Advent Life Sciences · British Patient Capital | ↗ |
| SPINOUTOther financing | May 2019 | $0 | — | University of Southampton | — |
Growth signals
Latest recorded traffic for Curve Therapeutics is 210 monthly website visits, down 90.5% over the last three months. Curve Therapeutics's team declined 2.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Curve Therapeutics in the Southampton ecosystem
The Curve Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Epidarex Capital
Columbus Venture Partners
Advent Life Sciences
British Patient Capital- PVPfizer Ventures
Other known investors1 additional known investor
University of Southampton
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Curve Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Curve Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










